Skip to main content
PMC home page
Emergency Medicine Journal : EMJ logoLink to Emergency Medicine Journal : EMJ
. 2003 Jul;20(4):339–346. doi: 10.1136/emj.20.4.339

Pharmacological management of agitation in emergency settings

A Yildiz 1, G Sachs 1, A Turgay 1
PMCID: PMC1726160  PMID: 12835344

Abstract

Objective: To review, firstly, published studies comparing classic antipsychotics, benzodiazepines, and/or combination of both; and secondly, available data on the use of atypical antipsychotic medications in controlling agitation and aggressive behaviour seen in psychiatric patients in emergency.

Method: In the first review, studies comparing antipsychotics, benzodiazepines, and combination of both; and in the second review, efficacy trials of atypical antipsychotics that include an active and/or inactive comparator for the treatment of acute agitation were identified and reviewed. Data from clinical trials meeting the inclusion criteria were summarised by recording improvement rates, definition of improvement, and timing of defined improvement for individual studies.

Results: In the first review, 11 trials were identified meeting the inclusion criteria, eight with a blind design. The total number of subjects was 701. These studies taken together suggest that combination treatment may be superior to the either agent alone with higher improvement rates and lower incidence of extrapyramidal side effects. In the review of atypical antipsychotic agents as acute antiagitation compounds, five studies were identified, three with a blind design. The total number of subjects was 711, of which 15% (104) was assigned to the placebo arm. This review found atypical antipsychotics to be as effective as the classic ones and more advantageous in many aspects.

Conclusion: Atypical antipsychotics such as risperidone, ziprasidone, and olanzapine with or without benzodiazepines should be considered first in the treatment of acute agitation. If these agents are not available the combination of a classic antipsychotic and a benzodiazepine would be a reasonable alternative. An oral treatment should always be offered first for building up an alliance with the patient and suggesting an internal rather than external locus of control.

Full Text

The Full Text of this article is available as a PDF (118.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen M. H. Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry. 2000;61 (Suppl 14):11–20. [PubMed] [Google Scholar]
  2. Barbee J. G., Mancuso D. M., Freed C. R., Todorov A. A. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry. 1992 Apr;149(4):506–510. doi: 10.1176/ajp.149.4.506. [DOI] [PubMed] [Google Scholar]
  3. Battaglia J., Moss S., Rush J., Kang J., Mendoza R., Leedom L., Dubin W., McGlynn C., Goodman L. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 1997 Jul;15(4):335–340. doi: 10.1016/s0735-6757(97)90119-4. [DOI] [PubMed] [Google Scholar]
  4. Bieniek S. A., Ownby R. L., Penalver A., Dominguez R. A. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy. 1998 Jan-Feb;18(1):57–62. [PubMed] [Google Scholar]
  5. Brook S., Lucey J. V., Gunn K. P. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry. 2000 Dec;61(12):933–941. doi: 10.4088/jcp.v61n1208. [DOI] [PubMed] [Google Scholar]
  6. Chouinard G., Annable L., Turnier L., Holobow N., Szkrumelak N. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry. 1993 Nov;38 (Suppl 4):S114–S121. [PubMed] [Google Scholar]
  7. Coffman J. A., Nasrallah H. A., Lyskowski J., McCalley-Whitters M., Dunner F. J. Clinical effectiveness of oral and parenteral rapid neuroleptization. J Clin Psychiatry. 1987 Jan;48(1):20–24. [PubMed] [Google Scholar]
  8. Currier G. W. Atypical antipsychotic medications in the psychiatric emergency service. J Clin Psychiatry. 2000;61 (Suppl 14):21–26. [PubMed] [Google Scholar]
  9. Currier G. W., Simpson G. M. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001 Mar;62(3):153–157. doi: 10.4088/jcp.v62n0303. [DOI] [PubMed] [Google Scholar]
  10. Daniel D. G., Potkin S. G., Reeves K. R., Swift R. H., Harrigan E. P. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001 May;155(2):128–134. doi: 10.1007/s002130000658. [DOI] [PubMed] [Google Scholar]
  11. Dorevitch A., Katz N., Zemishlany Z., Aizenberg D., Weizman A. Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry. 1999 Jan;156(1):142–144. doi: 10.1176/ajp.156.1.142. [DOI] [PubMed] [Google Scholar]
  12. Dubin W. R., Feld J. A. Rapid tranquilization of the violent patient. Am J Emerg Med. 1989 May;7(3):313–320. doi: 10.1016/0735-6757(89)90179-4. [DOI] [PubMed] [Google Scholar]
  13. Dubin W. R., Waxman H. M., Weiss K. J., Ramchandani D., Tavani-Petrone C. Rapid tranquilization: the efficacy of oral concentrate. J Clin Psychiatry. 1985 Nov;46(11):475–478. [PubMed] [Google Scholar]
  14. Farde L. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride. Psychopharmacology (Berl) 1992;107(1):23–29. doi: 10.1007/BF02244961. [DOI] [PubMed] [Google Scholar]
  15. Feifel D. Rationale and guidelines for the inpatient treatment of acute psychosis. J Clin Psychiatry. 2000;61 (Suppl 14):27–32. [PubMed] [Google Scholar]
  16. Fitzgerald P. Long-acting antipsychotic medication, restraint and treatment in the management of acute psychosis. Aust N Z J Psychiatry. 1999 Oct;33(5):660–666. doi: 10.1080/j.1440-1614.1999.00627.x. [DOI] [PubMed] [Google Scholar]
  17. Foster S., Kessel J., Berman M. E., Simpson G. M. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol. 1997 May;12(3):175–179. doi: 10.1097/00004850-199705000-00009. [DOI] [PubMed] [Google Scholar]
  18. Garza-Treviño E. S., Hollister L. E., Overall J. E., Alexander W. F. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry. 1989 Dec;146(12):1598–1601. doi: 10.1176/ajp.146.12.1598. [DOI] [PubMed] [Google Scholar]
  19. Jones B., Taylor C. C., Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry. 2001;62 (Suppl 2):22–24. [PubMed] [Google Scholar]
  20. Kinon B. J., Roychowdhury S. M., Milton D. R., Hill A. L. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry. 2001;62 (Suppl 2):17–21. [PubMed] [Google Scholar]
  21. Konikoff F., Kuritzky A., Jerushalmi Y., Theodor E. Neuroleptic malignant syndrome induced by a single injection of haloperidol. Br Med J (Clin Res Ed) 1984 Nov 3;289(6453):1228–1229. doi: 10.1136/bmj.289.6453.1228-d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kriwisky M., Perry G. Y., Tarchitsky D., Gutman Y., Kishon Y. Haloperidol-induced torsades de pointes. Chest. 1990 Aug;98(2):482–484. doi: 10.1378/chest.98.2.482. [DOI] [PubMed] [Google Scholar]
  23. Lesem M. D., Zajecka J. M., Swift R. H., Reeves K. R., Harrigan E. P. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001 Jan;62(1):12–18. doi: 10.4088/jcp.v62n0104. [DOI] [PubMed] [Google Scholar]
  24. Lindenmayer J. P. The pathophysiology of agitation. J Clin Psychiatry. 2000;61 (Suppl 14):5–10. [PubMed] [Google Scholar]
  25. McGough J. J., Bona J. R. Management of the agitated patient. A pharmacological update. N C Med J. 1988 Oct;49(10):497–499. [PubMed] [Google Scholar]
  26. Meehan K., Zhang F., David S., Tohen M., Janicak P., Small J., Koch M., Rizk R., Walker D., Tran P. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001 Aug;21(4):389–397. doi: 10.1097/00004714-200108000-00006. [DOI] [PubMed] [Google Scholar]
  27. Mehta D., Mehta S., Petit J., Shriner W. Cardiac arrhythmia and haloperidol. Am J Psychiatry. 1979 Nov;136(11):1468–1469. doi: 10.1176/ajp.136.11.1468. [DOI] [PubMed] [Google Scholar]
  28. Modestin J., Krapf R., Böker W. A fatality during haloperidol treatment: mechanism of sudden death. Am J Psychiatry. 1981 Dec;138(12):1616–1617. doi: 10.1176/ajp.138.12.1616. [DOI] [PubMed] [Google Scholar]
  29. Neborsky R., Janowsky D., Munson E., Depry D. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Behavioral considerations. Arch Gen Psychiatry. 1981 Feb;38(2):195–199. doi: 10.1001/archpsyc.1981.01780270081011. [DOI] [PubMed] [Google Scholar]
  30. Polak P., Laycob L. Rapid tranquilization. Am J Psychiatry. 1971 Nov;128(5):640–643. doi: 10.1176/ajp.128.5.640. [DOI] [PubMed] [Google Scholar]
  31. Richards J. R., Derlet R. W., Duncan D. R. Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med. 1998 Jul-Aug;16(4):567–573. doi: 10.1016/s0736-4679(98)00045-6. [DOI] [PubMed] [Google Scholar]
  32. Richards J. R., Derlet R. W., Duncan D. R. Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. Eur J Emerg Med. 1997 Sep;4(3):130–135. doi: 10.1097/00063110-199709000-00003. [DOI] [PubMed] [Google Scholar]
  33. Salzman C., Green A. I., Rodriguez-Villa F., Jaskiw G. I. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics. 1986 Jan;27(1 Suppl):17–22. doi: 10.1016/s0033-3182(86)72734-5. [DOI] [PubMed] [Google Scholar]
  34. Salzman C., Solomon D., Miyawaki E., Glassman R., Rood L., Flowers E., Thayer S. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry. 1991 Apr;52(4):177–180. [PubMed] [Google Scholar]
  35. Schaffer C. B., Shahid A., Javaid J. I., Dysken M. W., Davis J. M. Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients. J Clin Psychopharmacol. 1982 Aug;2(4):274–277. [PubMed] [Google Scholar]
  36. Tesar G. E. The agitated patient, Part I: Evaluation and behavioral management. Hosp Community Psychiatry. 1993 Apr;44(4):329–331. doi: 10.1176/ps.44.4.329. [DOI] [PubMed] [Google Scholar]
  37. Thomas H., Jr, Schwartz E., Petrilli R. Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Ann Emerg Med. 1992 Apr;21(4):407–413. doi: 10.1016/s0196-0644(05)82660-5. [DOI] [PubMed] [Google Scholar]
  38. Verma S. D., Davidoff D. A., Kambhampati K. K. Management of the agitated elderly patient in the nursing home: the role of the atypical antipsychotics. J Clin Psychiatry. 1998;59 (Suppl 19):50–55. [PubMed] [Google Scholar]
  39. Wright P., Birkett M., David S. R., Meehan K., Ferchland I., Alaka K. J., Saunders J. C., Krueger J., Bradley P., San L. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001 Jul;158(7):1149–1151. doi: 10.1176/appi.ajp.158.7.1149. [DOI] [PubMed] [Google Scholar]
  40. Wyant M., Diamond B. I., O'Neal E., Sloan A., Borison R. L. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol Bull. 1990;26(1):126–129. [PubMed] [Google Scholar]

Articles from Emergency Medicine Journal : EMJ are provided here courtesy of BMJ Publishing Group

RESOURCES